Discover
Otezla (apremilast) / AmgenAmgen Canada receives approval of marketing authorization transfer of Otezla for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis (Canada Newswire) - Feb 12, 2020 - "Today, Amgen Canada Inc...announced Health Canada's approval of the Marketing Authorization transfer of OTEZLA...from Celgene Corporation to Amgen Canada. This transfer is in line with Amgen Inc.'s previously announced acquisition of the worldwide rights to OTEZLA completed in November 2019. OTEZLA is approved in Canada for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy, and...for the treatment of active psoriatic arthritis..."Fumaderm (dimethyl fumarate) / Biogen; Ilumya (tildrakizumab-asmn) / Sun Pharma, Almirall; Skilarence (dimethyl fumarate) / AlmirallTRANSITION: Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy (clinicaltrials.gov) - Feb 11, 2020 - P4; N=250; Recruiting; Sponsor: Almirall, S.A.Cosentyx (secukinumab) / NovartisEfficacy and Safety of 2 Secukinumab Regimens in 90kg or More wt Group With Moderate/Severe Chronic Plaque Psoriasis (clinicaltrials.gov) - Feb 13, 2020 - P3; N=331; Active, not recruiting; Sponsor: Novartis Pharmaceuticals; Recruiting --> Active, not recruiting; Trial primary completion date: Feb 2020 --> Sep 2019Ilumya (tildrakizumab-asmn) / Sun Pharma, AlmirallA Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis (clinicaltrials.gov) - Feb 13, 2020 - P2/3; N=120; Recruiting; Sponsor: Sun Pharma Global FZE; Not yet recruiting --> RecruitingANB019 / AnaptysBioANB019 sales potential: $250M peak (Infinata) - Feb 14, 2020 - A subscription to Thomson ONE is required to gain full access to report 68635796; Page no: 8; REPORT TITLE: "Boehringer Ingelheim Pharma GmbH & Co. KG - Company report”; AUTHOR: Infinata, et al; DATE: 02/10/2020Skyrizi (risankizumab) / AbbVie, Boehringer IngelheimAbbVie's Skyrizi now listed on the Nova Scotia formulary for the treatment of moderate to severe plaque psoriasis (Canada Newswire) - Feb 13, 2020 - "AbbVie...announced today that Nova Scotia has listed SKYRIZI™ (risankizumab) on its provincial formulary for the treatment of moderate to severe plaque psoriasis. This announcement comes just two months after AbbVie successfully reached an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA). Nova Scotia joins Ontario, Alberta, Saskatchewan and Quebec in bringing a much-needed treatment to patients living with psoriasis."Ilumya (tildrakizumab-asmn) / Sun Pharma, AlmirallEfficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis (clinicaltrials.gov) - Feb 12, 2020 - P3; N=146; Not yet recruiting; Sponsor: Sun Pharma Global FZE; Trial completion date: Sep 2022 --> Apr 2024; Initiation date: Mar 2020 --> Sep 2020; Trial primary completion date: Sep 2021 --> May 2023Otezla (apremilast) / AmgenAPOLO: A Study of the Real-life Management of Psoriatic Arthritis Patients Treated With Otezla® (Apremilast) in Belgium (clinicaltrials.gov) - Feb 10, 2020 - P=N/A; N=106; Completed; Sponsor: Celgene; Active, not recruiting --> Completed
